Mode
Text Size
Log in / Sign up

18F-FDG PET/CT SUVmax and TLR are associated with increased microvascular invasion risk in HCCPET Imaging Biomarkers Help Predict Liver Cancer Risks

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider SUVmax as a validated metabolic marker for preoperative microvascular invasion risk in hepatocellular carcinoma.

This meta-analysis evaluated the utility of 18F-FDG PET/CT imaging biomarkers, specifically Tumor-to-normal liver uptake ratio (TLR) and maximum standardized uptake value (SUVmax), for predicting microvascular invasion (MVI) in patients with hepatocellular carcinoma. The analysis included a total of 2,023 patients.

Key findings indicate that both TLR and SUVmax are significantly associated with increased MVI risk. Specifically, TLR showed an OR of 2.577 (95% CI: 1.446-4.593, P=0.001), while SUVmax showed an OR of 1.272 (95% CI: 1.036-1.561, P=0.021). In multivariable analysis, SUVmax retained independent predictive value with an OR of 2.140 (95% CI: 1.244-3.681, P=0.006). The AUC for SUVmax was 0.819 (95% CI: 0.739-0.899), while the Rad-score showed a similar diagnostic discrimination with an AUC of 0.809 (95% CI: 0.762-0.857).

Limitations noted include the fact that multivariable evidence for TLR was derived from a single study and requires further validation. Additionally, a combined model of SUVmax and Rad-score could not be pooled as the effect size was not reported in the included radiomics studies. Clinically, SUVmax is supported as a metabolic marker for preoperative MVI risk assessment, while the complementarity of SUVmax and Rad-score remains a hypothesis.

How this fits prior evidence

This meta-analysis addresses a gap in the non-invasive assessment of microvascular invasion in hepatocellular carcinoma. While prior coverage has focused on genetic loci, systemic therapies like pembrolizumab and regorafenib, and local treatments like HAIC or TACE, this study provides evidence for using 18F-FDG PET/CT imaging biomarkers (SUVmax and TLR) to assess MVI risk. These findings complement existing knowledge on treatment selection by providing a metabolic marker for preoperative risk assessment.

Researchers analyzed data from over 2,000 patients with hepatocellular carcinoma, a type of liver cancer. The study looked at how specific imaging markers from PET scans could help predict microvascular invasion, which is a critical factor in determining how the cancer behaves.

The study found that two specific markers, known as TLR and SUVmax, were linked to a higher risk of microvascular invasion. While both showed a link, the SUVmax marker was identified as an independent predictor of risk. Another tool called a radiomics score showed similar results to the SUVmax marker in identifying risks.

Because this was a meta-analysis, it is important to note that some data came from limited sources. For example, the evidence for the TLR marker needs more validation from multiple studies. While these markers show promise for helping doctors assess risk before surgery, they are currently used as tools to help understand the cancer's behavior rather than as a definitive diagnostic rule.

What this means for you:
Specific PET scan markers show a link to higher risk of microvascular invasion in liver cancer patients.

Common questions

What are the specific markers used in the study?

The study looked at two main markers from PET scans: the tumor-to-normal liver uptake ratio (TLR) and the maximum standardized uptake value (SUVmax). Both markers were found to be significantly associated with an increased risk of microvascular invasion in patients with hepatocellular carcinoma.

How accurate is the SUVmax marker for predicting risk?

The SUVmax marker showed a strong link to increased risk. In a multivariable analysis, it remained an independent predictor with an odds ratio of 2.140. It also showed a high area under the curve (AUC) of 0.819 for predicting microvascular invasion.

Is the radiomics score a reliable tool?

The radiomics score (Rad-score) showed a similar level of diagnostic ability to the SUVmax marker. However, because of limited data in the studies, it is currently not possible to confirm how these two tools work together as a combined model.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
IntroductionThis study, through a meta-analysis, aimed to assess the predictive performance of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for microvascular invasion (MVI) in hepatocellular carcinoma (HCC).MethodsWeb of Science, Embase, PubMed, and Cochrane Library were comprehensively searched from database inception to January 13, 2026. EndNote 21was employed for literature screening and data extraction. Meta-analysis was carried out on the extracted data using Stata 15, MetaDisc 1.4, and MedCalc.ResultsIn total, 21 studies were included, involving 2,023 patients with HCC, of whom 890 were MVI+ and 1,133 were MVI–. In univariable analyses, both tumor-to-normal liver uptake ratio (TLR) (odds ratio [OR] = 2.577, 95% confidence interval [CI]: 1.446–4.593, P = 0.001) and maximum standardized uptake value (SUVmax) (OR = 1.272, 95% CI: 1.036–1.561, P = 0.021) were significantly associated with an increased MVI risk. After multivariable adjustment, SUVmax retained independent predictive value (OR = 2.140, 95% CI: 1.244–3.681, P = 0.006), whereas the multivariable evidence for TLR was derived from a single study and required further validation. AUC values for SUVmax and radiomics score (Rad-score) were 0.819 (95% CI: 0.739–0.899) and 0.809 (95% CI: 0.762–0.857), respectively, with relatively balanced values for sensitivity, specificity, and negative likelihood ratio.ConclusionThe available evidence supports SUVmax as one of the metabolic markers for preoperative MVI risk assessment in HCC, with Rad-score similar to SUVmax in diagnostic discrimination. The complementary value of the two markers was not demonstrated by this Meta-analysis, but rather derived from inferences proposed by external studies. Moreover, because the included radiomics studies did not report a pooled effect size for the combined model integrating SUVmax and Rad-score, a Meta-analysis targeting this model is currently not feasible. Therefore, the complementarity of SUVmax and Rad-score should be regarded as a hypothesis to be tested. In the future, multicenter, prospective radiomics studies with rigorous external validation are warranted to further explore a combined prediction model based on SUVmax and Rad-score. On this basis, an integrated assessment workflow should be gradually established, by which preoperative decisions are guided.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261289724.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.